<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110746</url>
  </required_header>
  <id_info>
    <org_study_id>VIAject -032J</org_study_id>
    <nct_id>NCT01110746</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy</brief_title>
  <official_title>A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biodel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biodel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Effect on Post-prandial Glycemia Safety, and
      Tolerability of Viaject 7 vs. Lispro Insulin during SC Insulin Pump Therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3 hour incremental area under the glucose curve after a standardized high glycemic index meal.</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Draize scores at insulin infusion site at 24 hour and 72 hour follow-up visits, frequency of discomfort with insulin infusion, and severity of discomfort with insulin infusion (ratings of mild, moderate, or severe).</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Formulation A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Formulation B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Viaject 7</intervention_name>
    <description>100IU/mL administered subcutaneously</description>
    <arm_group_label>Formulation A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LISPRO</intervention_name>
    <description>100IU/mL administered subcutaneously</description>
    <arm_group_label>Formulation B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females diagnosed with type 1 diabetes mellitus for at least 6 months

          2. Current usage of subcutaneous insulin pump treatment with one of the following pumps:

               -  Medtronic Paradigm速

               -  Animas速

               -  OmniPod速

               -  ACCU-CHEK Spirit速

          3. Age 18-75 years

          4. HbA1c of 6.0 - 9.0% at screening visit.

          5. Willingness to attend 9 clinic visits.

        Exclusion Criteria:

          1. Pregnancy or Lactation

          2. Renal insufficiency (serum creatinine of 2.0 mg/dL or greater).

          3. Anemia

          4. Congestive heart failure.

          5. Visual impairment preventing reading of glucose meter values or the ability to use an
             insulin pump or continuous glucose monitoring device.

          6. Active coronary artery disease or heart procedure within the past 4 months.

          7. Active foot ulceration.

          8. Severe peripheral arterial disease.

          9. Stroke within the past 6 months.

         10. Active alcohol abuse, substance abuse, or severe mental illness.

         11. Active cancer, except basal cell or squamous cell skin cancers.

         12. Major surgical operation within 30 days prior to screening.

         13. Seizure disorder (epilepsy).

         14. Any concurrent illness, other than diabetes, that is not controlled by a stable
             therapeutic regimen.

         15. Currently use of corticosteroids.

         16. History of major non-compliance.

         17. Use of an investigational drug within 30 days prior to screening.

         18. Bleeding disorder, treatment with warfarin, or low platelet count.

         19. Any insulin allergy

         20. Current complaints of major infusion site problems with commercially- available
             insulin preparations, such as frequent occurrence of infections, marked swelling or
             marked erythema.

         21. History of gastroparesis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oregon Health and Science University/Legacy Health System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <disposition_first_submitted>July 30, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>July 30, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 3, 2015</disposition_first_posted>
  <last_update_submitted>July 30, 2015</last_update_submitted>
  <last_update_submitted_qc>July 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

